Barbara Kiesewetter
Medical University of Vienna
Internal medicineSurgeryPathologyOncologyRetrospective cohort studyLymphatic systemImmunologyLenalidomideHelicobacter pyloriChemotherapyClarithromycinProgressive diseaseLymphomaMALT lymphomaMucosa-associated lymphoid tissueRituximabNuclear medicineCancer researchMedicineGastroenterology
98Publications
18H-index
1,056Citations
Publications 100
Newest
#1Christoph Kornauth (Medical University of Vienna)H-Index: 19
#2Tea Pemovska (Medical University of Vienna)H-Index: 2
Last. Philipp B. Staber (Medical University of Vienna)H-Index: 26
view all 70 authors...
Personalized medicine aims to match the right drug with the right patient by utilizing specific features of the individual patients' tumor. However, current strategies of personalized therapy matching only provide treatment opportunities for less than 10% of cancer patients. A promising method may be drug profiling of patient biopsies with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to...
Source
#1Marius E. Mayerhoefer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 33
#2Markus RadererH-Index: 79
Last. Lukas Nics (Medical University of Vienna)H-Index: 16
view all 13 authors...
Post-treatment evaluation of gastric mucosa-associated lymphoid tissue (MALT) lymphoma currently relies on esophagogastroduodenoscopy with histological assessment of biopsies. Overexpression of the G-protein-coupled C-X-C chemokine receptor type 4 (CXCR4) has been previously observed in MALT lymphoma. The aim of this prospective study was to evaluate PET with the novel CXCR4 tracer [68Ga]Pentixafor as a potential alternative to follow-up biopsies for assessment of residual disease (non-complete ...
Source
#1Barbara Kiesewetter (Medical University of Vienna)H-Index: 18
#2Philipp Riss (Medical University of Vienna)H-Index: 13
Last. Markus Raderer (Medical University of Vienna)H-Index: 79
view all 7 authors...
Adrenocortical carcinoma (ACC) is a rare malignancy characterized by aggressive biology and potential endocrine activity. Surgery can offer cure for localized disease but more than half of patients relapse and primary unresectable or metastasized disease is frequent. Prognosis of metastatic ACC is still limited, with less than 15% of patients alive at 5 years. Recent advances in understanding the molecular profile of ACC underline the high complexity of this disease, which is characterized by li...
Source
#1Markus Raderer (Medical University of Vienna)H-Index: 79
#2Barbara Kiesewetter (Medical University of Vienna)H-Index: 18
Source
#2Lisa M. KaiserH-Index: 4
Last. Markus Raderer (Medical University of Vienna)H-Index: 79
view all 12 authors...
Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. One of the major goals in this palliative setting is to develop chemotherapy-free treatments, which approach the efficacy of immunochemotherapies, but avoid chemotherapy associated toxicity in this often elderly patient population. The PI3K inhibitor copanlisib has recently shown remarkable...
Source
Medullary thyroid cancer (MTC) represents a rare neuroendocrine neoplasm originating from neoplastic C-cells in the thyroid gland. While localized disease is potentially curable with an optimized surgical approach, the number of relapses is high, and a considerable number of patients present with primary metastatic disease. Multidisciplinary management including standardized surveillance following surgery, but also early involvement of medical oncologists, is therefore important. Several oncogen...
Source
This year’s virtual version of the European Society for Medical Oncology (ESMO) presidential sessions included three “late breaking” non-small cell lung cancer (NSCLC) abstracts, discussing strategies for adjuvant therapy of localized disease and up-front treatment of advanced anaplastic lymphoma kinase(ALK)-positive lung cancer.
Source
#2E.G.E. de Vries (UMCG: University Medical Center Groningen)H-Index: 22
Background The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials. ESMO-MCBS scores assume valid research methodologies and quality trial implementation. Studies incorporating flawed design, implementation, or data analysis may generate outcomes that exaggerate true benefit and are not generalisable. Failure to either indicate or penalise s...
Source
#1Barbara Kiesewetter (Medical University of Vienna)H-Index: 18
#2Markus Raderer (Medical University of Vienna)H-Index: 79
Introduction: MALT (mucosa associated lymphoid tissue) lymphoma is a distinct type of B-cell lymphoma characterized by extranodal manifestation and an indolent clinical course with 10-year survival rates up to 90%. However, transformation to aggressive lymphoma may occur and treatment is indicated in case of symptomatic or progressive disease.Areas covered: This review covers clinical and biological features potentially related to prognosis and outcome of MALT lymphoma patients, as well as avail...
Source
#2Markus RadererH-Index: 79
Last. Alexander HaugH-Index: 35
view all 14 authors...
For PET imaging of mantle cell lymphoma (MCL), [18F]FDG (2-deoxy-2-[18F]fluoro-D-glucose) is the currently recommended radiotracer, although uptake is variable and bone marrow evaluation is limited. In this prospective study, we evaluated the novel CXCR4 (G-protein-coupled C-X-C chemokine receptor type 4) tracer [68Ga]Pentixafor in MCL patients, and compared it to [18F]FDG. Methods: MCL patients underwent [68Ga]Pentixafor-PET/MRI, and, if required for routine purposes, also [18F]FDG-PET/MRI, bef...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.